aTYR PHARMA (ATYR) Asset Utilization Ratio (2020 - 2026)

aTYR PHARMA's (ATYR) quarterly Asset Utilization Ratio came in at 0.0 in Q1 2026, up 15.64% quarter-over-quarter from 0.0 in Q4 2025.

Analysis

aTYR PHARMA (ATYR) Asset Utilization Ratio (2020 - 2026) Analysis & Trends

aTYR PHARMA (ATYR) has reported Asset Utilization Ratio for 6 consecutive years, with 0.0 the latest figure, recorded in Q1 2026.

For the quarter ending Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.0; the trailing twelve-month figure through Mar 2026 stood at 0.0 (changed N/A YoY), and the FY2025 full-year result was 0.0, down 7.37% from the prior year.
Asset Utilization Ratio grew to 0.0 in Q1 2026 per ATYR's latest filing, from 0.0 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.13 in Q4 2022 and bottomed at 0.0 in Q3 2025.
Historically, Asset Utilization Ratio has averaged 0.03 across 5 years, with a median of 0.01 in 2024.
The widest YoY moves for Asset Utilization Ratio: up 311.56% in 2023, down 97.78% in 2023.
Over 5 years, Asset Utilization Ratio stood at 0.13 in 2022, then plunged by 97.78% to 0.0 in 2023, then slipped by 13.19% to 0.0 in 2024, then decreased by 23.69% to 0.0 in 2025, then increased by 15.64% to 0.0 in 2026.
According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	0.40
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	0.58
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	0.47
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	0.38
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	0.20
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	-
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	0.90
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	0.33
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	0.00
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-	-

Historic Data

Download Data